AMENDMENT NO. 3 TO INTERIM PRODUCT SUPPLY AGREEMENTInterim Product Supply Agreement • November 22nd, 2022 • Legend Biotech Corp • Pharmaceutical preparations
This Amendment No. 3 to the Interim Product Supply Agreement (this “Amendment”) is made and effective as of November 16, 2022 (the “Amendment Effective Date”), by and among Legend Biotech USA Inc., a Delaware corporation (“Legend”), and Janssen Pharmaceuticals, Inc., a Pennsylvania corporation (“JPI”). Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in the Agreement.
AMENDMENT NO. 2 TO INTERIM PRODUCT SUPPLY AGREEMENTInterim Product Supply Agreement • November 22nd, 2022 • Legend Biotech Corp • Pharmaceutical preparations
This Amendment No. 2 to the Interim Product Supply Agreement (this “Amendment”) is made and effective as of October 17, 2022 (the “Amendment Effective Date”), by and among Legend Biotech USA Inc., a Delaware corporation (“Legend”), and Janssen Pharmaceuticals, Inc., a Pennsylvania corporation (“JPI”). Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in the Agreement.
AMENDMENT NO. 1 TO INTERIM PRODUCT SUPPLY AGREEMENTInterim Product Supply Agreement • July 13th, 2022 • Legend Biotech Corp • Pharmaceutical preparations
This Amendment No. 1 to the Interim Product Supply Agreement (this “Amendment”) is made and effective as of July 7, 2022 (the “Amendment Effective Date”), by and among Legend Biotech USA, Inc., a Delaware corporation (“Legend”), and Janssen Pharmaceuticals, Inc., a Pennsylvania corporation (“JPI”), and amends that certain Interim Product Supply Agreement between Legend and JPI entered into as of February 28, 2022 (the “Agreement”). Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in the Agreement.
INTERIM PRODUCT SUPPLY AGREEMENTInterim Product Supply Agreement • March 31st, 2022 • Legend Biotech Corp • Pharmaceutical preparations
This Interim Product Supply Agreement (the “Agreement”) is made as of February 28th, 2022 (“Agreement Date”) by and between, on the one hand, Legend Biotech USA, Inc., a Delaware corporation (“Legend”) and Janssen Pharmaceuticals, Inc., a Pennsylvania corporation (“JPI” and, together with Legend, the “Parties”).
